TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00263887
Drug: Alpha1-Proteinase Inhibitor (Human)
Normalized name: Alpha1-proteinase inhibitor (human)
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly infusion of 60 mg/kg body weight for 2 years
Study: NCT01140737
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
Study: NCT03278509
Drug: Metoprolol Succinate
Normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
Study: NCT03278509
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Please see the section above.
Study: NCT00055484
Drug: zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00030641
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03275857
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly IV
Study: NCT01288924
Drug: Parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
Study: NCT03211455
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous lidocaine versus placebo
Study: NCT03290313
Drug: shu gan yi yang capsule
Normalized name: Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
Study: NCT03290313
Drug: shu gan yi yang capsule simulation agent
Normalized name: Gan Cao Root
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
Study: NCT03129776
Drug: 18F-FDG
Normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
Study: NCT03601494
Drug: medical
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
Study: NCT02064140
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00799487
Drug: CONCERTA (methylphenidate HCl) or placebo
Normalized name: methylphenidate hydrochloride Extended Release Oral Tablet [Concerta]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
Study: NCT00080431
Drug: Daclizumab
Normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00799487
Drug: CONCERTA (methylphenidate HCl) or placebo
Normalized name: methylphenidate hydrochloride Extended Release Oral Tablet [Concerta]
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
Study: NCT03864211
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 1. Patients received toripalimab (240mg, Q3W) as monotherapy.~Protocol 2. Patients received toripalimab (240mg, Q3W) on day 3 after ablation.~Protocol 3. Patients received toripalimab (240mg, Q3W) on day 14 after ablation.
Study: NCT03884725
Drug: Fibrinogen Concentrate
Normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen Concentrate is to be administered as an intravenous infusion after discontinuation of cardiopulmonary bypass and administration of protamine. Subjects are to be given Fibrinogen Concentrate at an individually determined dose based on FIBTEM MCF and body weight as follows: (15 \[mm\] - MCF \[mm\]) \* body weight \[kg\] / 140 \[mm\*kg/g\] = gram fibrinogen to be dosed as Fibrinogen Concentrate. Fibrinogen Concentrate is to be infused over 1 to 2 minutes. After Fibrinogen Concentrate infusion, bleeding treatment will follow the predefined, standardized treatment regimen.
Study: NCT04481750
Drug: MT-1186
Normalized name: lipase
DrugBank: Pancrelipase (DB00085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution or suspension
Study: NCT00384995
Drug: 0.9% (154 mEq/L) IV Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution
Study: NCT00384995
Drug: 1/6 M (166 mEq/L) IV Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicarbonate solution
Study: NCT01120912
Drug: Oshadi Oral Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral insulin single administration
Study: NCT04608201
Drug: Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment involves escalating doses to the target dose of 14 mg / day~1. / Dose escalation:~   * Level 1: 3.5 mg/day (1/2 patch) for 2 days (D1 and D2)~  * Level 2: 7 mg/day (1 patch) for 2 days (D3 and D4)~  * Level 3: 10.5 mg/day (1.5 patch) for 2 days (D5 and D6)~  * Level 4: target dose = 14 mg/day (from D7 to discharge from hospital + 1 week or maximum 5 weeks after the start of treatment)~2. / Decrease in dose (1 week after exit from hospital or maximum 5 weeks after the start of treatment): Decrease of 3.5 mg (1/2 patch) per week (over 3 weeks maximum)
Study: NCT04608201
Drug: Placebo of NICOTINE Transdermal patch
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo of nicotine patch administered to the same administration schedule as in the experimental arm
Study: NCT02993419
Drug: Bacillus licheniformis Intervention
Normalized name: Bacillus licheniformis
DrugBank: Bacillus licheniformis (DB19247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
Study: NCT03838133
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 50 mg (0.5%, 10 mL)
Study: NCT01918761
Drug: Dacomitinib, Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500mg/m2 i.v (q21d) Dacomitinib 45mg orally (continuous)
Study: NCT00166452
Drug: Lenalidamide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02715232
Drug: Lynestrenol
Normalized name: lynestrenol
DrugBank: Lynestrenol (DB12474)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-3 tablets/day, if menstruation still occurs
Study: NCT02715232
Drug: Cyproterone Acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg daily
Study: NCT02715232
Drug: Triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
Study: NCT01321437
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
Study: NCT01009515
Drug: Paclitaxel, carboplatin, temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Combination chemotherapy was administered for up to 6 cycles
Study: NCT00456482
Drug: Fluocinolone Acetonide 0.59mg
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone Acetonide Intravitreal Implant 0.59 mg
Study: NCT00456482
Drug: Fluocinolone Acetonide 2.1mg
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone Acetonide Intravitreal Implant 2.1 mg
Study: NCT02675374
Drug: dexchlorpheniramine (Polaramine®) injection
Normalized name: dexchlorpheniramine maleate Oral Tablet [Polaramine]
DrugBank: Dexchlorpheniramine maleate (DB09555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
Study: NCT02462486
Drug: Abicipar Pegol
Normalized name: abicipar pegol
DrugBank: Abicipar Pegol (DB12258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abicipar pegol intravitreal injection.
Study: NCT02462486
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab intravitreal injection.
Study: NCT00075686
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 IV over 30 minutes
Study: NCT01767610
Drug: micronized fenofibrate 160mg
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01767610
Drug: pitavastatin Ca 2mg
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01767610
Drug: micronized fenofibrate 160mg plus pitavastatin Ca 2mg
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01216410
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
Study: NCT01216410
Drug: Phenylephrine infusion
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic phenylephrine infusion after spinal and placebo antiemetics
Study: NCT00983528
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose Escalation~Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9~Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5
Study: NCT04194554
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given PO per dose escalation schedule
Study: NCT04194554
Drug: Leuprolide
Normalized name: Leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.5 mg q3 month
Study: NCT04194554
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg daily
Study: NCT01558830
Drug: ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
Study: NCT03017950
Drug: CKD-330
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03799848
Drug: Vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral tablet
Study: NCT01082224
Drug: motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: motexafin gadolinium
Study: NCT03091257
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered Orally BID
Study: NCT03091257
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered Orally once daily
Study: NCT00275639
Drug: Cozaar
Normalized name: Cozaar
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00924586
Drug: ONO-1101
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for one minute IV
Study: NCT00924586
Drug: ONO-1101
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg/kg for one minute IV
Study: NCT01362673
Drug: PF-04171327
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single 5 mg dose as one 5 mg tablet
Study: NCT01362673
Drug: PF-04171327
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single 10 mg dose as one 10 mg tablet
Study: NCT01362673
Drug: PF-04171327
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single 30 mg dose as three 10 mg tablets
Study: NCT03017950
Drug: CKD-330 + D086
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00479661
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous infusion
Study: NCT00479661
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion
Study: NCT01362673
Drug: PF-04171327
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral multiple 20 mg doses as two 10 mg tablets for 12 days
Study: NCT01034462
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
Study: NCT00492687
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02546050
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00492687
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00492687
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03255044
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin administered as well as standard heart failure therapy
Study: NCT04080596
Drug: Dorzagliatin
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GKA for T2DM currently under clinical development
Study: NCT03710044
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment: Oral cyclosporine A (CsA) treatment (4-5 mg/kg/day) for 3 weeks.~Responders shift to oral low-dose CsA treatment (2-2.5 mg/kg/day) until onset of a second flare or until Week 16 (Day 113).~In case of a second AD flare, the subjects shift back to oral high-dose CsA treatment (4-5 mg/kg/day) for 3 weeks.
Study: NCT01706263
Drug: MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Available over the counter.
Study: NCT00233155
Drug: Capsaicin Dermal Patch
Normalized name: capsaicin Medicated Patch
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02063217
Drug: Sodium Oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate h.s.
Study: NCT00273416
Drug: PF-00592379
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00273416
Drug: Sildenafil 100mg
Normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00559364
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
Study: NCT04126343
Drug: Padsevonil
Normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive padsevonil in a pre-specified dosing sequence during the Treatment Period
Study: NCT04126343
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use~* Study participants will receive moxifloxacin once during the Treatment Period
Study: NCT04561336
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: avelumab in combination with cetuximab
Study: NCT04561336
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: avelumab in combination with cetuximab
Study: NCT01358084
Drug: NGR-hTNF
Normalized name: NGR-hTNF
DrugBank: Tengonermin (DB16689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
Study: NCT00398684
Drug: Single dose nevirapine to the mother and to the child
Normalized name: THE-630
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Study: NCT00398684
Drug: Single dose nevirapine to the mother and placebo to the child
Normalized name: THE-630
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Study: NCT00398684
Drug: Single dose placebo to the mother and to the child
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. \[Infants less than 2,500g received only 0.2mL/kg\]
Study: NCT01235442
Drug: 1=Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
Study: NCT01235442
Drug: 2=Clobetasol propionate foam
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
Study: NCT04490707
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Azacitidine
Study: NCT04490707
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elderly or unfit for intensive therapy patients with acute myeloid leukemia who had entered CR receive maintenance therapy contained Lenalidomide
Study: NCT00782561
Drug: FG-3019
Normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
Study: NCT01118845
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The administration of rituximab at 375 mg/m\^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
Study: NCT02743806
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab IV infusion
Study: NCT02574338
Drug: prostaglandin E1 analogue
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravaginal misoprostol
Study: NCT02979691
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04143295
Drug: Diiodothyropropionic acid (DITPA)
Normalized name: 3,5-diiodothyropropionic acid
DrugBank: 3,5-diiodothyropropionic acid (DB12629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Administration
Study: NCT00244829
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04440280
Drug: Visine Dry Eye Relief eye drops
Normalized name: POLYETHYLENE GLYCOL 400 10 mg in 1 mL OPHTHALMIC SOLUTION/ DROPS [Visine Dry Eye Relief Eye Drops]
DrugBank: Polyethylene glycol 400 (DB11077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visine Tears Dry Eye Relief artificial tears ophthalmic solution
Study: NCT02402491
Drug: 12 months of P2Y12 receptor antagonist
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.